The largest private hospital groups in Saudi Arabia and The Philippines look likely to IPO in the next 12 months, while the private sale of pan-Asian group Columbia Asia also nears completion. In total, the deals could be worth $6-7bn.
Italy's second-largest nursing home group by revenue, Gruppo KOS, has entered Germany for the first time with the acquisition of fast-growing residential care group Charleston. We discuss multiples and market dynamics with a sector expert.
As first reported by HBI, dialysis group Diaverum looks certain to be sold by Bridgepoint. Reuters now suggests that Diaverum is "exploring" and "testing the appetite" for a €2bn sale of the global dialysis group Diaverum. We go through potential buyers.
Japan has a large and thriving for-profit elderly care sector and leads the world with its long-term insurance policy that is mandatory for everyone over 40. We talk to Matt McEnany, a manager at the Japanese think tank Health and Global Policy Institute about the Japanese care and hospital sectors, the direction of reform, the market share of the top five for-profit groups in care and plans to export the Japanese model.
Hong Kong investment firm New Frontier Corp has acquired one of China's largest private hospital groups, creating one of the country's largest publicly listed integrated healthcare companies.
We talk to pan-European imaging and outpatient group Affidea CEO Giuseppe Recchi about its recent acquisition spree and AI partnerships. He says its pipeline of acquisitions will double its size in the next two years.
Spain's second and fourth-largest private hospital groups are reportedly in discussions to merge to create a new challenger to the market biggest player, Fresenius-owned Quironsalud. And Vithas has just pinched the number one's COO.
Three German ministries have come together to tackle the country's nursing staff crisis, proposing "binding measures" to be implemented next year. HBI speaks to a domiciliary care provider which is enthusiastic about these changes, but the legislation has already encountered problems.
Ophthalmology operators look set to pay the price of a new EU regulation. The European Device Regulation comes into force in May next year, and medtech suppliers are likely to pass the additional costs this places onto them on.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.